Rapid Micro Biosystems (NASDAQ:RPID) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Rapid Micro Biosystems has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Lake Street Capital has recently initiated coverage with a "buy" rating and an $8.00 price target.
• The company's stock saw a 6.3% increase on Friday, opening at $2.85, with a 52-week range between $0.80 and $4.50.
• In its latest earnings report, Rapid Micro Biosystems missed EPS estimates, reporting ($0.27) against a consensus of ($0.26), despite exceeding revenue expectations at $7.26 million.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

Separately, Lake Street Capital started coverage on shares of Rapid Micro Biosystems in a research note on Monday, July 28th. They set a "buy" rating and a $8.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Strong Buy" and a consensus target price of $8.00.

Rapid Micro Biosystems Stock Up 6.3%

Shares of Rapid Micro Biosystems stock opened at $2.85 on Friday. Rapid Micro Biosystems has a 52-week low of $0.80 and a 52-week high of $4.50. The company's 50-day simple moving average is $3.35 and its 200-day simple moving average is $2.99. The firm has a market cap of $124.92 million, a price-to-earnings ratio of -2.82 and a beta of 1.32.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01). Rapid Micro Biosystems had a negative return on equity of 63.07% and a negative net margin of 145.63%.The firm had revenue of $7.26 million for the quarter, compared to analyst estimates of $7.10 million. Rapid Micro Biosystems has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Rapid Micro Biosystems will post -1.1 EPS for the current year.

Insiders Place Their Bets

In other Rapid Micro Biosystems news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $3.32, for a total transaction of $39,444.92. Following the transaction, the chief executive officer directly owned 970,550 shares in the company, valued at approximately $3,222,226. This represents a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 57,443 shares of company stock worth $195,952 in the last quarter. Corporate insiders own 29.96% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ABG WTT Global Life Science Capital Partners GP Ltd grew its position in Rapid Micro Biosystems by 78.0% during the first quarter. ABG WTT Global Life Science Capital Partners GP Ltd now owns 1,848,296 shares of the company's stock worth $4,880,000 after buying an additional 810,000 shares during the period. Parkman Healthcare Partners LLC purchased a new stake in shares of Rapid Micro Biosystems in the first quarter valued at about $1,942,000. Geode Capital Management LLC lifted its holdings in shares of Rapid Micro Biosystems by 1.6% in the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company's stock valued at $704,000 after purchasing an additional 3,143 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Rapid Micro Biosystems by 122.9% in the fourth quarter. Renaissance Technologies LLC now owns 183,087 shares of the company's stock valued at $165,000 after purchasing an additional 100,942 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new stake in shares of Rapid Micro Biosystems in the first quarter valued at about $467,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.